Skip to main content

Abstract

Objective:

Two-thirds of individuals identified as at ultra-high risk for psychosis do not develop psychotic disorder over the medium term. The authors examined outcomes in a group of such patients.

Method:

Participants were help-seeking individuals identified as being at ultra-high risk for psychosis 2–14 years previously. The 226 participants (125 female, 101 male) completed a follow-up assessment and had not developed psychosis. Their mean age at follow-up was 25.5 years (SD=4.8).

Results:

At follow-up, 28% of the participants reported attenuated psychotic symptoms. Over the follow-up period, 68% experienced nonpsychotic disorders: mood disorder in 49%, anxiety disorder in 35%, and substance use disorder in 29%. For the majority (90%), nonpsychotic disorder was present at baseline, and it persisted for 52% of them. During follow-up, 26% of the cohort had remission of a disorder, but 38% developed a new disorder. Only 7% did not experience any disorder at baseline or during follow up. The incidence of nonpsychotic disorder was associated with more negative symptoms at baseline. Female participants experienced higher rates of persistent or recurrent disorder. Meeting criteria for brief limited intermittent psychotic symptoms at intake was associated with lower risk for persistent or recurrent disorder.

Conclusions:

Individuals at ultra-high risk for psychosis who do not transition to psychosis are at significant risk for continued attenuated psychotic symptoms, persistent or recurrent disorders, and incident disorders. Findings have implications for ongoing clinical care.

Formats available

You can view the full content in the following formats:

Supplementary Material

File (appi.ajp.2014.13030418.ds001.pdf)

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 249 - 258
PubMed: 25727537

History

Received: 28 March 2013
Revision received: 2 April 2014
Revision received: 7 August 2014
Accepted: 25 August 2014
Published ahead of print: 7 November 2014
Published online: 1 March 2015
Published in print: March 01, 2015

Authors

Affiliations

Ashleigh Lin, Ph.D.
From the Telethon Kids Institute, University of Western Australia, Subiaco; the School of Psychology, University of Birmingham, Edgbaston, Birmingham, U.K.; the Melbourne Neuropsychiatry Centre, Melbourne, Australia; the Institute of Brain, Behaviour, and Mental Health, University of Manchester, Manchester, U.K.; and Orygen Youth Health Research Centre, Melbourne, Australia.
Stephen J. Wood, Ph.D.
From the Telethon Kids Institute, University of Western Australia, Subiaco; the School of Psychology, University of Birmingham, Edgbaston, Birmingham, U.K.; the Melbourne Neuropsychiatry Centre, Melbourne, Australia; the Institute of Brain, Behaviour, and Mental Health, University of Manchester, Manchester, U.K.; and Orygen Youth Health Research Centre, Melbourne, Australia.
Barnaby Nelson, Ph.D.
From the Telethon Kids Institute, University of Western Australia, Subiaco; the School of Psychology, University of Birmingham, Edgbaston, Birmingham, U.K.; the Melbourne Neuropsychiatry Centre, Melbourne, Australia; the Institute of Brain, Behaviour, and Mental Health, University of Manchester, Manchester, U.K.; and Orygen Youth Health Research Centre, Melbourne, Australia.
Amanda Beavan, B.Sc.
From the Telethon Kids Institute, University of Western Australia, Subiaco; the School of Psychology, University of Birmingham, Edgbaston, Birmingham, U.K.; the Melbourne Neuropsychiatry Centre, Melbourne, Australia; the Institute of Brain, Behaviour, and Mental Health, University of Manchester, Manchester, U.K.; and Orygen Youth Health Research Centre, Melbourne, Australia.
Patrick McGorry, M.D., Ph.D., F.R.A.N.Z.C.P.
From the Telethon Kids Institute, University of Western Australia, Subiaco; the School of Psychology, University of Birmingham, Edgbaston, Birmingham, U.K.; the Melbourne Neuropsychiatry Centre, Melbourne, Australia; the Institute of Brain, Behaviour, and Mental Health, University of Manchester, Manchester, U.K.; and Orygen Youth Health Research Centre, Melbourne, Australia.
Alison R. Yung, M.D., F.R.A.N.Z.C.P.
From the Telethon Kids Institute, University of Western Australia, Subiaco; the School of Psychology, University of Birmingham, Edgbaston, Birmingham, U.K.; the Melbourne Neuropsychiatry Centre, Melbourne, Australia; the Institute of Brain, Behaviour, and Mental Health, University of Manchester, Manchester, U.K.; and Orygen Youth Health Research Centre, Melbourne, Australia.

Notes

Address correspondence to Dr. Lin ([email protected]).

Funding Information

Colonial Foundation:
National Health and Medical Research Council10.13039/501100000925: 350241, 566529
Janssen Research and Development10.13039/100005205:
Supported by National Health and Medical Research Council (NHMRC) program grants (350241 and 566529) to Drs. Yung, Wood, and McGorry, by the Colonial Foundation, and by an unrestricted research grant from Janssen-Cilag. Dr. Wood was supported by NHMRC Career Development Awards. Dr. Nelson was supported by a Ronald Phillip Griffith Fellowship and an NHMRC Career Development Fellowship. Dr. Yung is the recipient of a NHMRC Senior Research Fellowship. Dr. Lin is supported by an NHMRC Early Career Fellowship. No funding source played any role in the collection, analysis, interpretation, or publication of data.Dr. McGorry currently receives research support from the National Health and Medical Research Council of Australia and the Colonial Foundation; he has also received grant funding from NARSAD and unrestricted research funding from AstraZeneca, Eli Lilly, Janssen-Cilag, Pfizer, and Novartis, as well as honoraria for educational activities with AstraZeneca, Eli Lilly, Janssen-Cilag, Pfizer, Bristol-Myers Squibb, Roche, and the Lundbeck Institute. Dr. Yung has received an unrestricted research grant from Janssen Cilag and honoraria from Janssen Cilag and Autifony Therapeutics. The other authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Full Text

View Full Text

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share